Tower Research Capital LLC TRC Acquires 10,695 Shares of CorMedix Inc. (NASDAQ:CRMD)

Tower Research Capital LLC TRC grew its holdings in CorMedix Inc. (NASDAQ:CRMD) by 325.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,981 shares of the company’s stock after acquiring an additional 10,695 shares during the quarter. Tower Research Capital LLC TRC’s holdings in CorMedix were worth $53,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CRMD. Steward Partners Investment Advisory LLC increased its stake in shares of CorMedix by 3.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 138,008 shares of the company’s stock valued at $519,000 after buying an additional 4,195 shares during the period. Beacon Pointe Advisors LLC bought a new position in shares of CorMedix in the 4th quarter worth $90,000. Advisor OS LLC raised its position in CorMedix by 20.0% in the 4th quarter. Advisor OS LLC now owns 30,000 shares of the company’s stock valued at $113,000 after buying an additional 5,000 shares during the last quarter. Jump Financial LLC purchased a new stake in CorMedix in the 4th quarter valued at $266,000. Finally, MJP Associates Inc. ADV purchased a new stake in CorMedix in the 4th quarter valued at $94,000. Institutional investors own 34.18% of the company’s stock.

Insider Transactions at CorMedix

In other news, CEO Joseph Todisco purchased 13,561 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were bought at an average price of $3.74 per share, for a total transaction of $50,718.14. Following the completion of the transaction, the chief executive officer now owns 352,839 shares in the company, valued at $1,319,617.86. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. JMP Securities reissued a “market outperform” rating and issued a $19.00 price objective on shares of CorMedix in a report on Tuesday, April 9th. Royal Bank of Canada decreased their price objective on CorMedix from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Wednesday, March 13th. Truist Financial decreased their price target on CorMedix from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, January 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of CorMedix in a research note on Tuesday, April 9th.

CorMedix Price Performance

Shares of CorMedix stock traded down $0.03 during trading hours on Tuesday, reaching $5.26. The company’s stock had a trading volume of 372,911 shares, compared to its average volume of 545,407. The firm has a 50 day moving average price of $4.34 and a 200-day moving average price of $3.72. CorMedix Inc. has a one year low of $2.57 and a one year high of $7.00. The stock has a market cap of $288.03 million, a P/E ratio of -5.71 and a beta of 1.86.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). As a group, sell-side analysts forecast that CorMedix Inc. will post -0.83 EPS for the current fiscal year.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.